Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Advances in multiple myeloma from ASH 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.12.12
Views: 29559

Prof Thierry Facon - Centre Hospitalier Universitaire, France

Professor Thierry Facon from Lille, France, talks to ecancer TV about the treatment options currently available in multiple myeloma (MM) and future directions.


He outlines current standard care in induction, consolidation therapy post stem cell transplantation, and maintenance therapy. He notes the differences around Europe in current care.


Professor Faconcomments on the current and potential future use of bortezomib both in transplant eligible and ineligible patients. He also notes the important on-going trials with lenalidomide in transplant ineligible patients.


Professor Facon looks forward to the large phase III trials due to report results in 2013, such as MM-020 in over 1600 stem cell ineligible elderly patients (³65 years) receiving lenalidomide plus low-dose dexamethasone or melphalan, prednisolone, thalidomide.  Also, the final results of the IFM lenalidomide maintenance study. He also notes the interesting and promising phase I/II results seen to date with single agent daratumumab, a human CD38 monoclonal antibody, in relapsed myeloma patients with advanced disease, and notes the extensive clinical trial programme for this new agent.  Other promising agents in the late-breaking ASH session were pomalidomide (the phase III 003 study in relapsed/refractory MM) and the investigational drug MLN9708.  Professor Facon also notes newer drugs that have shown early promise, such as ARRY-520. 


This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Related videos

follow us

WIN 2020

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation